News and Announcements
Universal Biosensors Product Update
- Published April 01, 2016 3:36PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st April 2016, ASX Announcement
Universal Biosenors (ASX:UBI) provides below an update to its product development pipeline.
The company has been conducting a review of its current development projects with a view to prioritising development spend and focusing on projects that most enhance shareholder value.
Associated with this review, UBI management have also noted the eligibility criteria to access the R&D cash rebate which is important to UBI’s net cash flow. In particular, it is a condition of the program that the annual revenue remains below $20 million. It makes very little sense for UBI to chase short term small revenue increases that will take our revenue above this limit.
To view the full article please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
